DNY59
- Viatris (NASDAQ:VTRS) has obtained an exclusive license to market Lexicon Pharmaceuticals’ (NASDAQ:LXRX) drug sotagliflozin outside of the United States and Europe for all indications.
- Under the agreement, Lexicon will receive an upfront payment of $25M, with the potential for milestone payments plus tiered